<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03016260</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00556-45</org_study_id>
    <nct_id>NCT03016260</nct_id>
  </id_info>
  <brief_title>RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis</brief_title>
  <acronym>RABIOPRED</acronym>
  <official_title>Proof-of-Performance Study of RABIOPRED Assay as an In Vitro Diagnostic Test to Identify Patients With Rheumatoid Arthritis Who Are Unlikely to Show Response to 1st Treatment With Anti-TNFα and Methotrexate Combination.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TcLand Expression S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TcLand Expression S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RABIOPRED is an in vitro non-invasive blood test, which aims to identify patients with
      rheumatoid arthritis (RA) who are not likely to respond to anti-TNFα and methotrexate
      combination therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-centre, non-interventional, open-label, non-comparative, prospective cohort study with
      a clinical follow-up between (a) 12 and 14 weeks and (b) 22 and 24 weeks.

      The RABIOPRED test is indicated for use in patients:

        -  18 years of age or older,

        -  Eligible for a first line biologic therapy with anti-TNF alpha. The RABIOPRED test is
           indicated for use by rheumatologists as a biological basis for guiding anti-TNF alpha
           treatment prior to its initiation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EULAR response criteria</measure>
    <time_frame>13th week (+/- 7 days)</time_frame>
    <description>Performance of RABIOPRED test to predict treatment response of anti-TNFα agents based on the EULAR (EUropean League Against Rheumatism) response criteria at 13th week (+/- 7 days) compared with baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR response criteria</measure>
    <time_frame>13th week (+/- 7 days)</time_frame>
    <description>Performance of RABIOPRED test to predict treatment response of anti-TNFα agents based on ACR (American College of Rheumatology) response criteria at 13th week (+/- 7 days) compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EULAR response criteria</measure>
    <time_frame>23rd week (+/- 7 days) or at the time of treatment switch</time_frame>
    <description>Performance of RABIOPRED test to predict treatment response of anti-TNFα agents based on the EULAR (EUropean League Against Rheumatism) response criteria at 23rd week (+/- 7 days) or at the time of treatment switch (whichever comes first) compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDAI (Simplified Disease Activity Index) score</measure>
    <time_frame>23rd week (+/- 7 days) or at the time of treatment switch</time_frame>
    <description>Performance of RABIOPRED test to predict treatment response of anti-TNFα agents based on achieving Low Disease Activity (LDA) according to SDAI score at 23rd week (+/- 7 days) or at the time of treatment switch (whichever comes first) compared with baseline.</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">720</enrollment>
  <condition>RheumatoId Arthritis</condition>
  <arm_group>
    <arm_group_label>Infliximab (Remicade®)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab (Humira®)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept (Enbrel®)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab (Simponi®)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Certolizumab Pegol (Cimzia®)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab biosimilar (Remsima®/ Inflectra®)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept biosimilar (Benepali®)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab biosimilar (Flixabi®)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Anti-TNF alpha originator</description>
    <arm_group_label>Infliximab (Remicade®)</arm_group_label>
    <other_name>Remicade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Anti-TNF alpha originator</description>
    <arm_group_label>Adalimumab (Humira®)</arm_group_label>
    <other_name>Humira®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Anti-TNF alpha originator</description>
    <arm_group_label>Etanercept (Enbrel®)</arm_group_label>
    <other_name>Enbrel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Anti-TNF alpha originator</description>
    <arm_group_label>Golimumab (Simponi®)</arm_group_label>
    <other_name>Simponi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Certolizumab Pegol</intervention_name>
    <description>Anti-TNF alpha originator</description>
    <arm_group_label>Certolizumab Pegol (Cimzia®)</arm_group_label>
    <other_name>Cimzia®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab biosimilar</intervention_name>
    <description>Anti-TNF alpha Infliximab biosimilars</description>
    <arm_group_label>Infliximab biosimilar (Remsima®/ Inflectra®)</arm_group_label>
    <other_name>Remsima® or Inflectra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept biosimilar</intervention_name>
    <description>Anti-TNF alpha Etanercept biosimilar</description>
    <arm_group_label>Etanercept biosimilar (Benepali®)</arm_group_label>
    <other_name>Benepali®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab biosimilar</intervention_name>
    <description>Anti-TNF alpha Infliximab biosimilar</description>
    <arm_group_label>Infliximab biosimilar (Flixabi®)</arm_group_label>
    <other_name>Flixabi®</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, RNA, Plasma, Serum, PBMC and Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from rheumatoid arthritis eligible for biologic therapy, for whom the
        rheumatologist envisages anyone of anti-TNFα, will be included in this study. As the study
        should not modify patient care, it is not authorized to prescribe study biologics if other
        biologic is considered for a given patient or if a given patient is not eligible for study
        biologic treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a confirmed Rheumatoid Arthritis according the American College of
             Rheumatology (ACR) classification criteria (Arnett FC, 1988, Arthritis Rheum)

          -  Patient with a DAS28 index greater than 3.2.

          -  Patient eligible for treatment with an anti-TNFα agent (any one of Remicade®, Humira®,
             Enbrel®, Simponi®, Cimzia®, Remsima®/Inflectra®, Benepali® and Flixabi® according to
             the &quot;Summary of Product Characteristics&quot; for each product) and Methotrexate
             combination therapy,

          -  Patient refractory to treatment with at least one classical DMARDs (one of which has
             to be MTX) prescribed according to the international recommendations, i.e. for at
             least 12 weeks at the maximal tolerated dose prior to anti-TNFα treatment and with
             doses which must have been kept stable during the 4 weeks preceding the initiation of
             the anti-TNFα therapy. In case of Leflunomide treatment, patients may be included in
             the study after a period of at least 3 months of Leflunomide stop, or after a washout
             by cholestyramine for at least 11 days.

          -  Use of oral steroids (≤ 10 mg/day of prednisone or equivalent dose of another
             molecule) and/or NSAIDs will be permitted; doses must have been kept stable during the
             4 weeks preceding the initiation of the anti-TNFα therapy

          -  Patient (male or female) at 18 years of age or older at inclusion,

          -  Negative β-HCG (Human Chorionic Gonadotrophin) pregnancy test, when appropriate,
             according to the patient's age and contraceptive method.

          -  Written Informed consent signed from the patient.

        Exclusion Criteria:

          -  Patient having received previously any anti-TNFα biologic therapy or any molecule in
             development belonging to anti-TNFα class. Patients having received other biologics
             (such as anti-CD20, anti-CTLA4, IL1 blockers, IL6 blockers and other molecules in
             development) can be included in the study after a period of at least 6 months,

          -  Patient non eligible to anti-TNFα according to the SmPC (Summary of Products),

          -  Patient on anti-TNFα monotherapy without methotrexate,

          -  Patient with clinically significant, severe and uncontrolled infectious diseases,

          -  Patient with symptoms of a significant somatic or psychiatric/mental illness,

          -  Patient with other auto-immune diseases (i.e. Inflammatory Bowel Diseases, Systemic
             Lupus Erythematosus, vasculitis, uncontrolled asthma, etc.),

          -  Patient with evidence of cardiac, pulmonary, metabolic, renal, hepatic,
             gastro-intestinal conditions, which, in the opinion of the Investigator, may interfere
             with the study,

          -  Cancer,

          -  Pregnancy,

          -  Nursing mothers,

          -  Patient who is participating in a clinical trial of other biologics or for whom a
             period of exclusion has been defined
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Madah Mehdi</last_name>
    <phone>+33 (0) 3 89 91 13 20</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hüseyin Firat</last_name>
    <phone>+33 (0) 3 89 91 13 20</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiří Vencovský</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU-Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Jorgensen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Breuil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques-Eric Gottenberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Surasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadir Arber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tom Huizinga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmet Gül</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Marmara</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nevsun Inunç</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2017</study_first_submitted>
  <study_first_submitted_qc>January 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2017</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Anti TNF</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Golimumab</keyword>
  <keyword>Certolizumab Pegol</keyword>
  <keyword>Infliximab biosimilar</keyword>
  <keyword>Etanercept biosimilar</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

